Page 2 - Michael Benkowitz News Today

United Therapeutics Corporation (NASDAQ:NASDAQ:UTHR) Q3 2022 Earnings Conference Call November 02, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine...

03.08.2022 - United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared ...

The FDA has approved Tyvaso DPI (treprostinil) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.

United Therapeutics Corporation (NASDAQ:NASDAQ:UTHR) Q1 2022 Results Conference Call May 04, 2022 09:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson,...

Investegate announcements from Ferrer, Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease

PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today...

UTHR earnings call for the period ending September 30, 2021.

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United...

/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug...